Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial

Ken Kato^*, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya-Chanaga, Apurva Patel, Nan Hu, Yasuhiro MatsumuraYuko Kitagawa, Jaffer Ajani

^*Kontaktforfatter

KI, OUH, Forskningsenhed for Onkologi (Odense)

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Osaka University
The Royal Marsden NHS Foundation Trust
Chinese PLA General Hospital
Klinika Onkologii i Radioterapii
Akita University Hospital
Kanagawa Cancer Center Research Institute
Kindai University Faculty of Medicine
National Taiwan University Hospital
Institut du Cancer de Montpellier
Centre Oscar Lambret
National Cancer Institute of Milan
University of São Paulo
The University of Texas MD Anderson Cancer Center
Bristol-Myers Squibb
ONO Pharmaceutical Company
Keio University School of Medicine

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial

Fingeraftryk

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology